Novo Nordisk's Failed Heart Drug Trial Deepens a Season of Setbacks
Published on 08/02/2026 at 06:24 | Redaktion boerse-global.de
The Danish pharmaceutical giant Novo Nordisk is heading into its second-quarter earnings report under a cloud of mounting disappointments, the latest being Friday's disclosure that its experimental anti-inflammatory drug Ziltivekimab failed to achieve its primary goal in a pivotal Phase III trial.
Shares closed Friday at EUR 40.90, down 8.48% on the day, extending a slide that has left the stock 25.45% below its 52-week high of EUR 54.86 reached in January. The stock is also down 7.10% year-to-date, and over three years it has lost 36.4% of its value.
A Null Result in the ZEUS Trial
The ZEUS study enrolled 6,315 patients with atherosclerotic cardiovascular disease, systemic inflammation, and chronic kidney disease. The results were unambiguous: Ziltivekimab produced a hazard ratio of 0.99 with a confidence interval of 0.88 to 1.11, meaning no statistically significant difference from placebo in reducing major adverse cardiovascular events.
While the drug did lower inflammatory markers including CRP and sTNFR1 as expected, that biomarker improvement failed to translate into clinical benefit. The treatment group actually saw more serious infections, and overall mortality was essentially unchanged from placebo.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Novo Nordisk acquired the antibody in 2020 through its $725 million takeover of Corvidia, betting that targeting inflammation could open a new avenue in cardiovascular prevention. That bet has now soured, though the company says two related studies, HERMES and ARTEMIS, are still running, with results expected in the first half of 2027. A non-cash impairment charge will be booked in the third quarter of 2026, but the company maintains its 2026 operating profit guidance remains unaffected.
Ripple Effects Across the Biotech Sector
The market reaction extended beyond Novo Nordisk itself. Shares of other biotech companies with inflammation programs came under pressure as investors began questioning whether hsCRP is a reliable predictor of clinical benefit. Monte Rosa Therapeutics was hit hardest, falling 27.5%, while BioAge Labs, Neurocrine, and Neumora also declined.
Analysts at Jefferies and Citi described the market response as overdone, though they acknowledged the strategic setback: Ziltivekimab was meant to help diversify Novo Nordisk beyond its diabetes and obesity franchise, which reportedly still accounts for roughly 94% of group revenue.
A Stock That Looks Cheap — For a Reason
On valuation, the stock trades at a price-to-earnings ratio of 11.1, well below the industry average of 14.9 and the comparison group's 24.7. A fair-value model puts the appropriate P/E at 23.0, and by that calculation the stock passes five of six standard valuation criteria. Some market observers see a potential buying opportunity given the still-growing global GLP-1 market, but the technical picture is more nuanced: the shares remain about 1.35% above their 200-day moving average, while an RSI of 41.8 points to neither oversold conditions nor an imminent rebound.
A Series of Unfortunate Events
The ZEUS disappointment is just the latest in a string of setbacks. Earlier, a failed study of an oral semaglutide variant in roughly 4,000 Alzheimer's patients — which showed no slowing of disease progression — sent the stock down more than 10% in Copenhagen. CEO Mike Doustdar subsequently announced an 11% workforce reduction, equivalent to roughly 9,000 jobs, to be implemented starting in September. The company has also cut its revenue guidance four times this year.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
On the commercial front, Novo Nordisk is reshaping its U.S. pricing strategy. Starting January 1, 2027, list prices for Wegovy, Ozempic, and Rybelsus will be unified at $675 per month — a reduction of about 50% for Wegovy and roughly 35% for Ozempic. Jamey Millar, EVP of U.S. Operations, said the move aims to improve access for patients with high deductibles or cost-sharing requirements, while existing self-pay programs will continue unchanged.
New Data Offers Some Counterweight
On the product side, the company is leaning on new clinical data. A high-dose version of Wegovy at 7.2 milligrams achieved an average weight loss of 27.7% after 72 weeks in an analysis presented at the European Congress on Obesity, compared with 17% for the current maximum dose of 2.4 milligrams. Three major U.S. pharmacy benefit managers have already added the higher dose to their reimbursement lists — a partial counter to Eli Lilly's Zepbound, which has shown more than 20% weight loss.
What Wednesday's Numbers Will Tell
All eyes now turn to Wednesday, when Novo Nordisk reports its second-quarter results. Analysts expect earnings per share of around $5.09 on revenue of roughly $72.6 billion. With the ZEUS failure, the Alzheimer's disappointment, ongoing legal proceedings with Eli Lilly, and the fourth guidance cut already behind it, the report will test how resilient the core Wegovy and Ozempic business truly is — and whether the company holds its current annual outlook.
Ad
Novo Nordisk Stock: New Analysis - 2 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
